Skip to main content

Table 3 Summary of evidence for outcomes of postoperative adjuvant therapies in the included studies

From: The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

Intervention vs comparison Design Studies Outcome Patients (n) ES (95% CI)
Pa-TACE vs conservation therapy RCT and retrospective study 8 OS 1646 HR 0.64 (0.55–0.74). I2 = 4.2%
Pa-TACE vs conservation therapy RCT and retrospective study 9 RFS 1696 HR 0.70 (0.62–0.78). I2 = 0%
Pa-TACE vs radiotherapy retrospective study (PSM) 2 OS 178 HR 1.75 (0.92–3.32). I2 = 0%
Pa-TACE vs radiotherapy retrospective study (PSM) 2 RFS 178 HR 2.29 (1.43–3.65). I2 = 0%
Pa-TACE vs re-resection/ radiofrequency ablation ablation retrospective study (PSM) 2 OS 129 HR 0.65 (0.09–4.89) p = 0.671, I2 = 89.3%
Sorafenib vs conservation therapy retrospective study 1 OS 49 HR 0.219 (0.071–0.672)
Sorafenib vs conservation therapy retrospective study 1 RFS 49 HR 0.308 (0.131–0.724)
  1. Pa-TACE postoperative adjuvant transarterial chemoembolization, PSM propensity score matching, RCT randomized double-blind controlled clinical trial